14.12.2009 • NewsLundbeck

Lundbeck Buys Neuronicon Danish pharmaceuticals group

H. Lundbeck has agreed to buy privately owned Danish biotechnology firm Neuronicon to gain technologies for treating brain damage. Lundbeck, whose main products are anti-depressants and which hopes to grow in neurological treatments. The financial details were not disclosed. At the same time, Lundbeck signed a deal to cooperate with University of Arhus scientists on further neurology research over the next three years, the company said. NeuronIcon was founded by scientists at the University of Aarhus and is based on research conducted there and at the University of Berlin, Lundbeck said.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read